Breakthrough Cancer Pain Clinical Trial
Official title:
A Phase I/IIa, Pharmacokinetic, Dose-response and Safety Study of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With Breakthrough Cancer Pain
Breakthrough cancer pain (BTcP) is a common problem in patients with cancer. This is a phase I/IIa, pharmacokinetic, dose-response and safety study of inhaled fentanyl aerosol (25µg/dose) in Chinese patients with breakthrough cancer pain. The study will include two stages.
Stage I: dose-response relationship and safety assessment of inhaled fentanyl aerosol in patients with breakthrough cancer pain. placebo-controlled, cross-over, double-blind randomized design is applied in this stage. Patients meeting the inclusion/exclusion criteria will be treated with inhaled fentanyl aerosol (4 of 6 episodes BTcp) or placebo (2of 6 episodes BTcp).Subjects will inhale fentanyl aerosol or placebo for each episode of BTcp with a starting dose of 25 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×25 µg. Stage II: The dosage regimen (number of puffs) will be depended on the data from Stage I. Subjects will inhale fentanyl aerosol not in the episode of breakthrough cancer pain with a starting dose of 25 µg every 4 minutes. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01946555 -
Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain
|
N/A | |
| Recruiting |
NCT01698645 -
Patient Satisfaction and Quality of Life Impact - PecFent®
|
N/A | |
| Recruiting |
NCT01693328 -
Patient Satisfaction and Quality of Life Impact - PecFent®
|
N/A | |
| Completed |
NCT01936636 -
Observational Registry Study of Quality of Life When Treating BTcP With Abstral
|
N/A | |
| Completed |
NCT03669263 -
A Dose Titration Study of Fentanyl Buccal Soluble Film for Breakthrough Cancer Pain in Taiwan
|
N/A | |
| Completed |
NCT02899884 -
Characterisation and Epidemiology of Breakthrough Cancer Pain in Spain
|
||
| Recruiting |
NCT03564548 -
Inhaled Cannabinoids Versus Immediate-release Oral Opioids for the Management of Breakthrough Cancer Pain
|
Phase 2 | |
| Completed |
NCT03895762 -
Observational Study of Efficacy, Safety and Tolerability of Fentanyl in Korean Cancer Patients
|
||
| Terminated |
NCT01439919 -
A Clinical Trial to Assess the Clinical Benefit of SSR411298 as Adjunctive Treatment for Persistent Cancer Pain
|
Phase 2 | |
| Completed |
NCT01045603 -
Instanyl® Non-Interventional Study
|
N/A | |
| Recruiting |
NCT00822614 -
Safety of Fentanyl TAIFUN Treatment
|
Phase 3 | |
| Terminated |
NCT04468490 -
Treatment of Breakthrough Cancer Pain According to European Guidelines
|